ABOUT GULSINE

The scientific company behind A2P2

Gulsine is a specialist materials-science company building the infrastructure for mechanism-driven product-lifetime decisions. Its core asset is A2P2: a patented framework and protected platform for determining material-specific activation behaviour, acceleration factors and study designs.

Read how A2P2 came about →

THE PEOPLE BEHIND A2P2

Dr Nazli Gulsine Ozdemir

Dr Nazli Gulsine Ozdemir

CEng FIMMM

FOUNDER AND SCIENTIFIC LEAD

Dr Ozdemir has more than fifteen years of experience in polymer ageing, medical-device materials and product-lifetime assessment. She leads ASTM work relating to accelerated ageing and experimental Q₁₀ determination and contributes as a UK expert within ISO medical-device lifecycle work.

Her work connects first-principles materials science with the practical demands of R&D, quality systems, regulatory submissions and commercial product release.

“The reasonable man adapts himself to the world: the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man.”George Bernard Shaw

30 productsmanaged from concept to product release, from bioreactors to filtration systems

Global instructionher accelerated-ageing validation strategy for biopharmaceutical devices was adopted by Sartorius in 2023

INDUSTRYSartoriusSolvayZotefoamsFNSS

ACADEMIAUoBKU LondonSabancı UniversityMETU

Prof Steven Abbott

Prof Steven Abbott

A2P2 APPLICATIONS

Prof Abbott has a PhD in Chemistry from work in Oxford and Harvard, and did a post-doc with Nobel Prize winner J-M Lehn in Strasbourg. He worked in industry at ICI and as Research Director at a coatings company, and was made Visiting Professor at the School of Mechanical Engineering at the University of Leeds.

Now independent, he brings good science to life through software, apps and app-linked books, and works with corporations around the world as a troubleshooter using his own app-based approach.

WHAT GULSINE BUILDS

A2P2 is designed to become an internal enterprise capability—not a dependency on repeated one-off consulting.

01

Licensethe framework

02

Establisha foundational programme around a lead product

03

Transferthe methods into their laboratories

04

Builda governed knowledge base across their portfolio

IP PORTFOLIO

Patented in the UK, under examination in Europe, pending in the US

1

GRANTED

2

ALLOWED FOR GRANT

1

UNDER EXAMINATION

3

PENDING

STATUSOFFICENUMBERDETAIL
GRANTEDUKGB2639843Application GB2404188.1 · granted 1 April 2026
ALLOWED FOR GRANTUKGB2605212.6Prediction AI
ALLOWED FOR GRANTUKGB2518812.9Divisional application (GB2644619)
UNDER EXAMINATIONEPEP25159512.0Published as EP4621674 A1
PENDINGUKGB2518440.9Divisional application
PENDINGUKGB2518802.0Divisional application
PENDINGUS19/074,590Published as US 2026/0268341 A1

ENTERPRISE ENQUIRIES

Bring A2P2 inside your organisation

NAZLI@GULSINELTD.COM